HCM · LONDON STOCK EXCHANGE ·
HUTCHMED China Ltd
KRAS-EGFR-Antibody licensing deal with GSK closes
Our AI’s take
The announcement confirms the finalization of HUTCHMED’s exclusive license of its KRAS‑EGFR antibody‑drug conjugate HMPL‑A830 to GSK, with GSK receiving…
The full digestion is for members. What is good, what is bad and why, the numbers that matter, and the chart, then ask about it by voice or text.
Join freeNew to announcements? Learn what an RNS is and why prices move.